CNXU - From Accumulation to Momentum Expansion!

601
As highlighted in our previous analysis (attached on the chart), CNXU has now officially broken above its accumulation structure and appears to be entering the next phase of the move.⚠️

Following the initial Nasdaq debut volatility and post-IPO correction, bulls managed to reclaim the upper bound of the accumulation range, signaling that momentum may be shifting back in favor of buyers.📈

📊From a technical perspective, this breakout is important because fresh IPOs often transition through clear market structure phases:
• Initial price discovery
• Post-IPO correction
• Accumulation
• Markup phase


And CNXU now appears to be entering that markup phase.

📈As long as bulls maintain control above the previous accumulation zone, we will be looking for trend-following long opportunities on every correction.

Since CNXU is still a newly listed stock with limited historical price data, traditional resistance zones remain relatively undeveloped.

Because of that, psychological round numbers become increasingly important during price discovery.

🎯Targets:
• First bullish objective: $15
• Second bullish objective: $20
• Beyond that, price discovery remains largely open if momentum expansion continues. 🚀


📰From a fundamental perspective, CNXU continues attracting speculative attention through its regenerative medicine narrative and 3D biofabrication technologies.

The company recently introduced its B.R.E.A.S.T.™ bio-regenerative tissue platform, designed to move reconstruction beyond traditional implants and toward biologically supported tissue regeneration. 🧬

In brief, CNXU appears to be transitioning from accumulation into markup, while fresh price discovery conditions continue supporting momentum expansion.

⚠️ Disclaimer: This is not financial advice. Always do your own research and manage risk properly.

📚 Stick to your trading plan regarding entries, risk, and management.

Good luck! 🍀

All Strategies Are Good; If Managed Properly!
~Richard Nasr

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.